The biotech sector, as measured by the XBI ETF, rallied sharply in the pre-market session, driven by a broader market rotation out of large-cap technology stocks and into healthcare. This rotation was supported by a wealth of positive company-specific news, including favorable clinical trial results from companies like Rapport Therapeutics and Disc Medicine, an FDA approval for Alvotech, and optimistic analyst coverage for others. This suggests a renewal of investor interest in a sector that had been previously lagging.